Effect of canagliflozin on white blood cell counts in patients with type  2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial

ConclusionsOur findings suggest that 24  weeks of treatment with canagliflozin, relative to glimepiride, reduced WBC counts in patients with type 2 diabetes and heart failure.

Source: Journal of Diabetes Investigation - September 17, 2022 Category: Endocrinology Authors: Atsushi Tanaka, Takumi Imai, Michio Shimabukuro, Ikuko Nakamura, Kazuo Matsunaga, Yukio Ozaki, Tohru Minamino, Masataka Sata, Koichi Node, on behalf of the CANDLE trial investigators Tags: Original Article Source Type: research